A diverse population of regulatory B (Breg) cells reportedly exhibits significant immunomodulatory effects in various models of inflammatory responses and infectious diseases caused by bacteria, viruses or parasites. Breg cells contribute to maintenance of homeostasis via IL-10 production and multiple IL-10-independent mechanisms. The current review describes various phenotypic and functional subsets of Breg cells in autoimmune and infectious diseases and discusses the impacts of experimental conditions that have been found to drive Breg cell differentiation.
B lymphocytes play important roles in humoral responses because of their ability to produce immunoglobulins. Two distinct populations of B cells have been identified. B1 lymphocytes are characterized by constitutive expression of CD5. These cells are unable to switch the classes of produced antibodies; they respond to Tindependent antigens and their activation does not elicit B memory cell development (1) . B1 lymphocytes predominantly produce natural IgM antibodies. However, IgM immunoglobulins produced by the B1a subset express high affinity to antigen because they have Vregion mutations caused by activation-induced cytidine deaminase (2) , as observed in pneumococcal pneumonia (3) . In contrast, B2 lymphocytes do not express CD5 on their surfaces and require T cell help to activate primary immune responses. Interaction with helper T lymphocytes results in production of pro-inflammatory cytokines, which promotes proliferation and maturation of B cells. At this stage, classes of immunoglobulins are switched, depending on cytokine stimulation, and the specificity of antibodies also significantly expands as a result of single nucleotide polymorphisms in the hypervariable regions of antibodies. B2 cells differentiate into plasma cells and memory B cells, resulting in induction of instant and highly specific immune response on next contact with the same antigen. Memory B cell-mediated secondary responses are organism's most effective defense mechanism against infectious diseases (1) .
Many regulatory mechanisms controlling cellular and humoral responses have been described. Excessive inflammatory processes can be limited by formation of immune complexes. Binding of an antibody to the antigen's determinant prevents binding of other determinants of that antigen by another antibody. Formed complexes with the pathogenic antigen are removed from the milieu, inhibiting stimulation of the immune response. Antigen-antibody complexes can also bind to Fc receptors on the surfaces of B cells, which leads to their antigen-specific inactivation. According to the Jerne's theory, the immune system functions as a network in which production of certain idiotypic antibodies stimulates release of anti-idiotypic immunoglobulins, which limit amounts of circulating antibodies after the pathogen has been removed from the organism and they are no longer needed (4, 5) . It has recently been found that B cells may also contribute to immune regulation by releasing antibody-free light chains. Our research has shown that suppressor T cell-derived exosomes carrying immune regulatory miRNA-150 are coated with antigen-specific antibody light chains, which ensures specific targeting by T cell exosomes of antigenpresenting cells expressing related antigenic determinants (2, (6) (7) (8) (9) (10) (11) . B lymphocytes also provide antibodycoated exosomes that can associate freely circulating extracellular miRNAs, allowing them to specifically target selected immune cells (12) . There is also a distinct population of Treg cells, which can inhibit both B and T lymphocytes via production of inhibitory cytokines such as IL-10 and TGF-b (4) . Recently a new population of regulatory cells among B lymphocytes has been widely studied; however, their origin and function remains unclear.
The role of Breg cells in immune-specific suppression of delayed-type hypersensitivity reactions was first suggested in 1974 (13) . Suppressive activity of B cells in an EAE model was also proposed in 1996, when B celldepleted animals were found to fail to recover less completely than non-depleted controls (14) . Since then, the role of B cells in producing IL-10 has been identified in many different models, including autoimmune and infectious diseases, transplant tolerance and anti-tumor immunity (15) (16) (17) . The main characteristic that defines Breg lymphocytes is production of IL-10; however, it has been shown that they can also play their regulatory role in an IL-10-independent manner. A regulatory cytokine, IL-10 is essential in maintaining immune homeostasis and protects the host from extensive inflammation. IL-10-dependent signaling results in suppression of secretion of pro-inflammatory cytokines and chemokines by leukocytes and inhibition of expression of cell-surface molecules that are involved in adhesion processes, co-stimulation and antigen presentation. Additionally, this regulatory cytokine enhances proliferation and differentiation of B lymphocytes. As well, IL-10 increases IgG 4 production and, in combination with TGF-b, induces switching of immunoglobulins towards IgA 1 and IgA 2 ; it also inhibits IL-4-stimulated IgE secretion (18) .
Breg cells suppress function and proliferation of T lymphocytes, especially Th1, Th17 and T FH cells, via both IL-10-mediated and IL-10-independent mechanisms (19) (20) (21) . Limited expansion of T cells involved in activation of production of antibodies by B cells results in decreased concentrations of immunoglobulins, especially IgGs, which, with the exception of IgG 4 , are capable of activating complement, an important element of innate humoral immunity. Additionally, Breg cells reportedly suppress the cellular component of antigen-non-specific immune responses by acting on macrophages, DCs, NK cells and NKT cells (22) (23) (24) (25) . This way, Breg cells are able to limit and moderate prolonged inflammatory processes before they become chronic and lead to destruction of the host's own cells. This function is perfectly justified after elimination of the pathogen from the organism; however, it can also facilitate its persistence in the host and lead to more severe disease. In contrast, dysfunction or lack of Breg cells may contribute to excessive inflammation and development of autoimmune disorders.
BREG CELL DIFFERENTIATION
B lymphocytes are mostly formed in red bone marrow, where they undergo selection involving removal of cells with autoreactive potential. IL-10-producing B cells can be found in mouse spleen at frequencies of 1%-3%, and also in smaller numbers in blood, lymph nodes, Peyer's patches, intestinal tissues and the central nervous system (26) . The process of Breg cell differentiation and the stage at which they acquire their regulatory capacity are still debatable. Two models for explaining their development have proposed. The first model suggests that there is a dedicated lineage of B cells and that expression of genes that are responsible for its suppressive function is controlled by a specific factor. This is supposedly similar to the thymus-derived Treg cell lineage, with a specific marker equivalent to Foxp3 (27) . However, no researchers have conclusively identified such a marker for Breg cell lineage yet, which suggests that the second model of Breg cell development is more likely. The second hypothesis assumes that Breg cells differentiate from any B cell in response to certain environmental stimuli. This idea is supported by the considerable heterogeneity of phenotypes of Breg cells. Certain studies suggest that not only B cells can develop a suppressive function: IL-10-producing Breg cells can differentiate into antibody-producing plasmablasts after in vitro and in vivo stimulation (27) . In recent years, many environmental factors and cytokines have been confirmed to induce formation of distinct Breg cell populations in vitro, through the BCR pathway, CD40 ligation or TLR signaling ( Table 1 ). Given that there is no specific phenotype signature for Breg cells, they possibly should be classified by their suppressive function in the immune system rather than by lineage or process of differentiation.
IL-10-PRODUCING BREG CELL SUBSETS
Breg cells can be assigned to a few subsets on the basis of their phenotypes. Unfortunately, even though distinct Breg cell populations have been documented in various diseases, specific marker panels have not yet been identified for many of them (31) . Discrepancies in Breg cell subset's phenotypes likely result from variations in stimulation methods and markers investigated. For now, we can only provide observations that have been reported with the proviso that some of the discussed subsets may be identical. In the future, it should be possible to establish certain procedures for activating Breg cells in each model type and develop panels of markers dedicated to their phenotyping, both of which would facilitate discrimination between Breg subsets.
Immature T2-MZP cells have been identified as the main IL-10 producers in the spleens of mice with CIA; they are characterized by the CD19þCD21 
CD1d
hi phenotype (32) . In vitro, T2-MZP cells have been found to proliferate both in response to BCR engagement and to LPS; this makes it possible to distinguish them from the MZ B cell subset, which respond to LPS stimulation, but not to BCR activation (33) . When the regulatory capacity of IL-10-producing T2 MZP B cells was investigated in an adoptive transfer, it was found that these cells protect mice from development of CIA (32) . Other studies have also confirmed that this cell subset mediates suppressive mechanism based on IL-10-induced changes in Treg vs Th1/Th17 frequencies, increasing the number of Tregs (19 (31, 34) . Splenic MZ B cells that have been directly activated by ACs in vivo reportedly show increased secretion of IL-10, which in turn is required for T cell release of IL-10, in a mouse model of inflammation induced by ovalbumin administered with CFA. In the same study, (35, 36) .
Within the B1 lineage, which is known to produce the majority of natural antibodies, there is a functionally distinct CD5þ B1a cell subset that is capable of IL-10 production after innate stimulation (31) . B1 cells occur primarily during the fetal and perinatal periods. After in vitro or in vivo stimulation of TLR9, neonatal mouse B1a cells can suppress production of pro-inflammatory cytokines (TNF-a, IL-12p70/p40 and IL-6) by neonatal DCs, followed by inhibition of Th1 cell priming, via an IL-10-dependent mechanism (22, 37) . B1a cells (CD19þCD43þIgD lo IgM hi ) are also a major Breg cell population; they respond to AC stimulation by producing IL-10. AC neoantigens seem to be the cause of the breakdown in immune tolerance that leads to development of autoimmune inflammatory diseases. In a mouse model of EAE, adoptive transfer of TLR7/8 ligand (R848)-activated B1a cells reportedly significantly reduces the severity of this disease. B1a cells can inhibit TNF-a production by macrophages and promote Treg cell responses in an IL-10-dependent manner. They also facilitate clearance of ACs by production of natural antibodies (38) . In this study, TLR stimulation increased CD1d expression by B1a cells, making the origin of this subset inconclusive given that co-expression of CD1d hi and CD5 had previously been attributed to a mouse Breg subset called B10 cells (31, 38) .
Because the B10 cell subset is known to exclusively produce IL-10, this term has been used in some studies to include all IL-10-producing subsets of Breg cells (26) . It has been demonstrated that B10 cells (CD1d hi CD5þ) can suppress inflammation upon ex-vivo stimulation with LPS, PMA and ionomycin (39) . An interaction with CD40L, which is expressed on activated CD4þ T cells, is required to induce both B10 cell suppressive function and IL-21 stimulation. Additionally, it has been shown that MHC II-deficient mice lack functional B10 cells, which suggests that expression of MHC II is also necessary for this B cell subset to acquire its regulatory capacity (40) . A population of human B10 cells, described as CD19þCD24 hi CD27þ, has been found in the peripheral blood of patients with autoimmune diseases. Human B10 cells have been identified as able to acquire expression of cytoplasmic IL-10 after ex-vivo stimulation with CD40L and CpG. During antigendriven in vitro assays, activated human B10 cells were found to be able to inhibit TNF-a production in specific CD4þ T cells; however, the addition of anti-IL-10 antibody to the culture did not rescue TNF-a expression. Thus, human B10 cells possibly inhibit the effector function of antigen-specific CD4þ T cells in an IL-10-independent manner. CD24 hi CD27þ B cells also regulate TNF-a expression in monocytes; however, this mechanism is IL-10-mediated (41) .
A similar phenotype of Breg cells that shares the features of mouse B10 cells, T2-MZP B cells and plasmocytes has been identified in GIFT15-treated, spleen-derived B cells. GIFT15, a recently created fusokine, has been found to be a powerful immunosuppressive compound that can reprogram na€ ıve B cells into Bregs. GIFT15 was made by artificial fusion of two cytokines, namely granulocyte macrophage-colony stimulating factor and IL-15 (42) . GIFT15-induced Breg cells have been found to secrete IL-10 and to be B220, CD1d, CD21, CD22, CD23, CD24, CD43, CD79b, CD138, IgD and IgM positive, whereas they do not express CD19. Rafei et al. have demonstrated that GIFT15-induced Breg cells inhibit IFN-g secretion as third-party cells in antigen-driven responses. Additionally, their suppressive function has been shown to be partly, but not entirely, dependent on signal transducer and activator of transcription 6 and IL-10 (43).
Human CD19þCD24 hi CD38 hi B cells reportedly possess a regulatory capacity, having been found to be potent IL-10 producers upon CD40 stimulation. When cultured with T cells in the presence of anti-CD3 antibody, this cell subset suppresses IFN-g and TNF-a secretion by CD4þ T cells, but is unable to inhibit Th17 cell differentiation under the same conditions. According to Blair et al., the regulatory action of these Breg cells seems to be dependent on IL-10 production and CD80/ CD86 signaling because addition of anti-CD80 or anti-CD86 antibodies suppresses their function. In contrast, blockade of TGF-b has no impact on the ability of CD19þCD24 hi CD38
hi B cells to inhibit CD4þ T cell effector mechanisms (21) .
Breg cells expressing CD138þ on their surfaces are a significant source of IL-10 in mouse spleen and bone marrow. These cells have characteristics of both plasmablasts and plasma cells. Suzuki-Yamazaki et al. have identified them as IgMþB220 l°C D138 hi (44) . In an EAE model, CD138þ plasma cells were also found to be the main source of IL-35, which is reportedly a critical factor in regulation of T cell-mediated autoimmunity.
These plasma cells, which are derived from spleens and lymph nodes, have been identified as CD138 hi IgMþ TACIþCXCR4þCD1d hi Tim1 int (45) . IL-10-producing CD138þCD44 hi plasmablasts have been identified in the same mouse model. Interestingly, they were found only in draining lymph nodes, but not in the spleen (46) .
OTHER MECHANISMS OF IMMUNE REGULATION DRIVEN BY B CELLS
Apart from IL-10 production, different subsets of Breg cells can act through various other IL-10-independent mechanisms, including the above-mentioned IL-35 production, restriction of T cell differentiation, induction of FasL-mediated apoptosis of effector T cells, adenosine generation, granzyme B production and upregulation of PD-1 on Treg cells (47) ( Table 2) .
A minor population of spleen CD5þ B cells has been shown to constitutively express FasL and to be an important mediator of CD4þ effector T cell apoptosis in a mouse model of Schistosoma mansoni infection. FasL expression is dependent on antigen stimulation and the presence of cytokines, IL-10 and IL-4 in particular (48) . Also, it has been shown that reduction in numbers of FasLþCD5þ B cells correlates with severity of arthritis in a mouse model of CIA (49) . FasL is a protein that is structurally homologous to TNF. Ligation of receptor Fas by FasL on the cell surface delivers a strong signal, instructing the cell to commit apoptosis. FasL-dependent cell death via induction of apoptosis of activated lymphocytes is crucial in limiting excessive inflammation at the end of an immune response. It also contributes to cytotoxic cell-mediated elimination of virus-infected and cancer cells (50) 
In this study, anti-FasL antibody were found to partly reduce this regulatory effect, which confirms that the Fas/FasL pathway is a possible regulatory mechanism provided by B10 cells (51) .
A population of Breg cells that are similar to MZ B cells and MZ-progenitor B cells has been found to express PD-L1 (programmed cell death-1) molecule in mice immunized with keyhole-limpet hemocyanin hi B cells regulate humoral response homeostasis through restriction of T FH cell expansion in spleen and lymph nodes. T FH cells are necessary for activation of antibody production in B2 cells. Thus, alongside a decrease in T FH cell frequencies, attenuation in immunoglobulin concentrations has also been observed, both in mice and humans. PD-L1 hi B cells suppress T cell differentiation by alterations in downstream signaling pathways, which are crucial for regulation of T cell proliferation and activation. Interestingly, it has also been reported that PD-L1 hi populations of B cells resist anti-CD20 treatment and that their survival depends on sequestration of B-cell activating factor from the milieu (20) .
A novel population of Breg cells expressing CD73 and CD39 was recently reported. This population of B cells seems to suppress inflammatory reactions through adenosine generation in an IL-10-independent manner. CD73 functions as an ectoenzyme that, together with CD39, catalyzes extracellular dephosphorylation of adenine nucleotides to adenosine (53) . It has previously been reported that extracellular adenosine is generated by a population of Treg cells and induces their proliferation and immunoregulatory activity. Furthermore, it can directly suppress immune responses through interaction with A2a/A2b receptors on the effector cells (54) . Co-expression of CD73 and CD39 has been identified on B1 cells (B220þCD23À), B2 cells (B220þCD23þAA4.1À) and B10 cells in mice and also on human peripheral B cells (53, 55) . During 5 days of activation with CD40L and IL-4, human CD73þ B cells reportedly acquire the ability to limit autologous CD4þ and CD8þ T cell proliferation in vitro (55) . Adoptive transfer of CD73þ B1 cells before administration of dextran sulfate sodium salt has been found to ameliorate the severity of the disease in a mouse model of experimental inflammatory colitis. Kaku et al. have also reported that the regulatory function of B cells through adenosine generation can be diminished by IL-10 deficiency. These findings suggest that using IL-10À/À mice to investigate an IL-10-dependent regulatory pathway in inflammatory diseases could provide misleading results (53) .
Another population of Breg cells that produce the active form of the cytotoxic serine protease-granzyme B (GrB cells) after stimulation with IL-21 has been identified in the blood of patients with solid tumors. This cell subset reportedly has a CD19þCD38þ CD1dþIgMþCD147þ expression signature. When activated with IL-21 and anti-BCR antibody, GrB cells are able to strongly suppress CD4þ T cell proliferation through degradation of T cell receptor z chain, but not by induction of T cell apoptosis (56) . It has been reported that B cells stimulated in that manner also express IL-10, CD25 and indoleamine-2,3-dioxygenase. Both GrB cells and IL-21-producing T cells have been found in the microenvironments of different types of tumor, including breast, ovarian, cervical, colorectal and prostate cancers. Although IL-21-induced GrB cells in tumors do not express CD5, it has been reported that the potential of CD5þ B cells to release granzyme B in response to viral stimuli is significantly greater than that of CD5-B cells (56) . A similar population of GrB cells has been identified In the blood of patients with untreated HIV infection; these cells show strong expression of CD5, CD43, CD86, and CD147, but not of IL-10. HIVactivated CD4þ T cells, which produce large amounts of IL-21 but lack CD40L expression, are able to induce GrB cell development, whereas co-culture of B and T cells in the presence of IL-21 and soluble CD40L multimers has been found to redirect B cell differentiation into plasma cells (57) . Significantly more numerous GrB cells without strong IL-10 expression have also been observed in rhesus macaques infected with simian immunodeficiency virus, which is an accepted animal model of HIV infection. The phenotype of these cells only partly corresponds with that of human GrB cells; they more strongly express CD5, CD10, CD25 and CD27 and show weaker expression of CD19, CD185 and HLA-DR. In this model, greater numbers of GrB cells were found in bone marrow than in spleen and blood (58) . Development of GrB cells may be a countermeasure to overwhelming viral replication in early antiviral responses. Additionally, GrB cell induction by viral antigens is significantly stronger in vaccinated individuals than in unvaccinated controls (59) . GrB cells, selected as CD3-CD56ÀCD14ÀCD19þGrBþ, have also been found in peripheral blood of healthy individuals and proved to negatively regulate Th1 and Th17 cells. In this study their mechanism of action was partly mediated by down-regulation of T cell receptor z chain and induction of T cell apoptosis (60) .
BREG CELLS IN AUTOIMMUNE DISEASES
There are many examples of the regulatory role of B lymphocytes in limiting excessive inflammation, especially in the pathogenesis of autoimmune disorders. SLE, a chronic inflammatory disease, is characterized by the presence of antinuclear antibodies, heart and kidneys being the main affected organs (61) . Human CD19þ CD24 hi CD38
hi Breg cells from healthy donors have been shown to have regulatory functions. However, when isolated from the blood of individuals with SLE, this cell subset seems to lack a similar suppressive capacity, as evidenced by it failing to inhibit production of proinflammatory cytokines by CD4þ T cells. Interestingly, these functionally impaired Breg cells have been identified only in the blood of individuals with SLE, and not in that from individuals with Sj€ ogren syndrome or osteoarthritis (21) . It has been suggested that differentiation of immature B cells into IL-10-producing CD24þCD38 shown to ameliorate autoimmunity in SLE mice; their effectiveness may be at least partly dependent on Breg cell expansion. Thus, MDSC transplantation seems to be a promising strategy for attenuating B cell-mediated autoimmune disorders (63) .
Multiple sclerosis, a T cell-dependent, autoimmune disease of the central nervous system, is characterized by destruction of the myelin sheath surrounding axons. An animal model of EAE is commonly used to represent human multiple sclerosis in basic studies of the pathomechanism of this disease (64). Matsushita et al. have reported that adoptive transfer of splenic CD1d hi CD5þ B cells into CD19À/À mice, can significantly reduce EAE severity via an IL-10-dependent mechanism, which indicates that IL-10-producing Breg cells are able to negatively regulate EAE development. Depletion of Breg cells by removing them before or at an early stage of the disease in vivo reportedly does not accelerate the onset of the disease, but does significantly worsen the EAE score. These findings suggest that IL-10-producing Breg cells are crucial down-regulatory forces in the initiation phase of EAE (65) . In other studies, adoptive transfer of PD-L1 hi B cells has also been shown to significantly suppress EAE in mice and to retard the course of the disease, both when transfer took place 7 days before or 7 days after immunization with the encephalitogenic peptide from myelin oligodendrocyte glycoprotein in CFA (20) . Interestingly, Bodhankar et al. have reported that estrogen fully protects mice from development of EAE symptoms, even in the absence of Treg cells, and that this estrogen-induced protection is associated with upregulation of PD-L1 on CD1d hi CD5þ B cells and further production of IL-10 by this cell subset (66) .
Rheumatoid arthritis, an inflammatory disease, is characterized by joint destruction. It can be associated with environmental and genetic risk factors. Lundy and Fox have reported that in CIA, an accepted animal model of human RA, the severity of joint inflammation varies widely between mice. Interestingly, these differences correspond with the percentage of CD5þCD19þ B cells, but not that of CD5-CD19þ B cells. Reduction of the number of CD5þCD19þ B cells correlates with more severe arthritis. This Breg cell subset has been noted to have strong FasL expression and to significantly increase apoptosis of arthritogenic T cells (49). Evans et al. reported the protective effect of IL-10-producing Breg cells of a phenotype consistent with T2-MZP cells, and assessed their role at different stages of CIA. They found that B cells produce considerably more IL-10 in the remission phase than in the acute phase or in healthy controls. Additionally, an adoptive transfer of T2-MZP B cells collected at the remission stage of CIA was found to protect recipient animals from developing arthritis or to be associated with less severe disease scores (32) . Another study concentrated on the role of GrB cells in the pathogenesis of RA in humans. There were fewer of them in the peripheral blood of individuals with RA than in that of healthy controls or individuals with osteoarthritis. A negative correlation between disease activity and GrB cell frequencies was also noticed. These findings indicate that development of RA may be related to impairment of the regulatory function of GrB cells and that they become significantly more numerous after antirheumatic therapy (60) . Apart from autoimmunity, Breg cell function has also been recognized in anti-infectious immune responses.
BREG CELLS IN PARASITIC DISEASES
Various studies have found that B cells produce IL-10 in response to stimulation with parasitic antigens; however, the precise role of IL-10-producing B cells in this type of infections needs more investigation. It has been demonstrated that Breg cells are able to suppress antigenspecific CD8þ and CD4þ T cell effector functions at the early stages of the disease in a murine model of visceral leishmaniasis; they can also inhibit generation of memory T cells after Leishmania donovani infection via an as yet undefined mechanism. Exposure to L. donovani in vitro induces development of two IL-10-producing populations of Breg cells, one CD5þCD1dþ/ÀCD23 lo , similar to MZ B cells, and another of CD5þCD1dþCD23 hi phenotype. In this study, the cytotoxic capacity of NK and NKT cells and function of Th1 cells were suppressed via an IL-10-dependent pathway (25) . A population of IL-10-producing CD5þCD1dþ B cells been in response to in vitro stimulation with Leishmania major has been identified. These cells reportedly affect susceptibility to L. major infection by supporting polarization of Th0 cells towards the Th2 phenotype and down-regulating IL-12 production by DCs (24) .
In S. mansoni infection, CD4þ T cell-mediated responses are stimulated by SEAs secreted by the worm eggs. In this model of infection, the regulatory role of B cells is based on induction of CD4þ T cell apoptosis via the Fas-FasL pathway. Breg cells that are responsible for immunomodulation in Schistosoma infection have been identified as FasL-expressing B1a cells (CD19þCD5þ). These findings indicate that expression of FasL on B1a cells depends both on stimulation with SEA and on CD4þ T cell-derived cytokines, this being determined by blockade of individual cytokines in culture supernatants. IL-10 and IL-4 have been shown to induce up-regulation of FasL on B cells activated by SEA in a dose-dependent manner; however, culture of B cells with cytokines alone, without SEA stimulation, was found to not affect FasL expression (48) . In another study, injection of S. mansoni eggs or SEA into na€ ıve mice was found to induce in vivo expansion of IL-10-producing B cells that were identified as MZ B cells. The increased numbers of Breg cells persisted for 4 weeks. It was suggested that MZ B cells bind and internalizs the Schistosoma antigens directly, with subsequent up-regulation of CD86 and IL-10 expression, both in vitro and in vivo, and that their function is not supported by marginal zone macrophages. Additionally, egg-or SEA-induced Breg cells are able to drive CD25þFoxp3þ Treg cell development ex vivo, which amplifies their regulatory capacity and thereby promotes parasite persistence in the host (67) .
Lymphatic filariasis, a chronic tropical disease, is caused by parasites, such as Wuchereria bancrofti, that are transmitted to humans through mosquitoes. Filariasis is characterized by impairment of the lymphatic system and often leads to abnormal, painful enlargement of the affected body part. Research conducted in India found significantly more numerous B1a cells expressing FasL than in endemic controls and that these increased numbers correlate positively with increased apoptosis of CD4þ T cells in blood samples from individuals infected with W. bancrofti. Additionally, plasma IL-10 concentrations were found to be positively correlated with FasL up-regulation on B1a cells, indicating that this cytokine may have the potential to modulate B cell FasL expression in filariasis, as was previously suggested for Schistosoma infection (68) .
BREG IN BACTERIAL INFECTIONS
IL-10-dependent mechanisms play an important role in regulation of immune responses in bacterial infections and, in some cases, B cells have been shown to be one of the main producers of this cytokine. Staphylococcus aureus, a potentially lethal opportunistic pathogen, can cause local skin or soft tissue infections, as well as systemic infections, including bacteremia, pneumonia, osteomyelitis, endocarditis and toxic shock syndrome. This pathogen has been shown to modulate hosts' immune responses via an IL-10-dependent mechanism, thus facilitating its persistence during infection (69, 70) . Leech et al. have reported that IL-10 is primarily produced by peritoneal resident CD11b int CD19þCD5þ B cells, which are equivalent to B1a cells, and are activated directly by S. aureus through TLR2 receptors. Interestingly, in acute S. aureus infection, the role of Breg cells may be critical for preventing dissemination of the bacteria and their loading locally in the peritoneum rather than leading to systemic infection. However, IL-10 also facilitates pathogen persistence during local infections by dampening down effector T cell responses. Thus, the role of IL-10-producing B1a cells seems to differ depending on the site of S. aureus infection (71) .
Infection with another gram-positive, but intracellular, bacterium, Listeria monocytogenes, has been demonstrated to be accompanied by CD1d hi CD5þ B cell expansion in mice. Increased numbers of B10 cells have been shown to be responsible for significant inhibition of clearance of the pathogen in an IL-10-dependent manner in vivo. Further studies using this model have shown that depletion of B10 cells enhances macrophage cytokine production and phagocytosis of the bacteria and reduces specific CD4þ T cell activation. Thus, B10 cell expansion promotes persistence of Listeria and contributes to the pathogenesis of infection by inhibition of macrophage activation and stimulation of the CD4þ T cells. It has also been suggested that the immunoregulatory role of B10 cells in Listeria infection depends solely on interactions with CD4þ T cells, given that it does not alter CD8þ T cell responses (72) .
Salmonella enterica, a gram-negative bacterium, can be further classified according to its antigen presentation into over 2600 different serovars. Non-typhoidal Salmonella infections are the main bacterial causes of acute gastroenteritis and lead to invasive, extra-intestinal systemic infections in up to 5% of cases (73) . Research findings indicate that Salmonella infection directly stimulates IL-10 production by CD19þCD138þ B cells in the spleen via TLR2 or TLR4 receptors and that this cytokine production is dependent on the myeloid differentiation factor 88 pathway. Rapid accumulation of IL-10-producing B cells favors systemic infections with S. Typhimurium in mice because it suppresses the protective functions of neutrophils, NK cells and inflammatory CD4þ T lymphocytes (74) .
BREG IN VIRAL INFECTIONS
IL-10-producing B cells have also been shown to contribute to the pathogenesis of some viral infections. Cen et al. demonstrated their role in a mouse model of Coxsackie virus B3-induced acute viral myocarditis, acute myocarditis being an inflammatory disease that is associated with autoimmune responses of T cells, most frequently triggered by a virus. In their study, Breg cells were identified as CD19þIL-10þ B cells and they were significantly more numerous in spleens of mice with Coxsackie virus B3-induced acute viral myocarditis than in a control group. Additionally, Breg cells were more numerous in the first week of the infection than in the second, indicating they play a role in the early stage of this infection (75) .
It has also been suggested that production of IL-10 by B cells is an immune evasion strategy of HIV-1 virus. HIV infection is a chronic disease, the persistence of which is conditioned by dysfunctional T cell responses and various anomalies in B cells (76, 77) . IL-10-producing B cells are reportedly more numerous in the peripheral blood mononuclear cells of untreated HIV-1 individuals, both at the early and chronic stages of infection, than in healthy donors. Their numbers also correlate directly with the virus load in the early phase of infection, but not in the chronic one. Breg cells identified in the peripheral blood mononuclear cells of HIV-1 infected individuals have inconsistent phenotype CD19þCD20þTIM-1þCD1d
hi/l°C D27þ/ÀCD38
hi/lo ; however, most IL-10-producing B cells have been found to be Tim-1 positive. CD19þTim-1þ B cells are able to suppress HIV-1-specific CD8þ and CD4þ T cell responses, the mechanism of this suppression being only partly IL-10-dependent (76) . This seems to be consistent with the previously mentioned studies, which indicate the role of granzyme B-producing B cells in HIV pathogenesis (57, 
CONCLUSION
The role and phenotypes of Breg cells have been widely studied. Here, we concentrated on various experimental settings and stimulation methods that lead to Breg cell differentiation. Even though there are few Breg cells in mouse spleen and human blood, they are reportedly distinctive immunoregulators in maintaining homeostasis. In infectious diseases Breg cells most likely facilitate pathogen survival at an early stage of infection. They inhibit pro-inflammatory cytokine production and NK, NKT and T cell activation but promote Treg cell differentiation, thus contributing to the development of chronic infection and greater disease severity. Conversely, in autoimmune disorders, Breg cell function is disrupted and adoptive transfer of stimulated Breg cells prevents the disease onset and alleviates its symptoms. What's challenging for researchers is that methods of stimulation of this cell population are still inconclusive, and that phenotypes of Breg cells described thus far, along with their mechanism of immunosuppression, vary between diseases. All these findings indicate that Breg cells are an important tool for modulation of the immune system and that comprehensive understanding of their activation mechanisms and function may assist in exploiting novel therapies.
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